Pharmacy World and Science

, Volume 17, Issue 1, pp 12–16

Selective digestive decontamination in multiple trauma patients: Cost and efficacy

Authors

  • A. Langlois-Karaga
    • PharmacyHôpital Nord
  • M. Bues-Charbit
    • PharmacyHôpital Nord
  • A. Davignon
    • PharmacyHôpital Nord
  • J. Albanese
    • Intensive Care UnitHôpital Nord
  • O. Durbec
    • Intensive Care UnitHôpital Nord
  • C. Martin
    • Intensive Care UnitHôpital Nord
  • N. Morati
    • Medical Information UnitHôpital Nord
  • G. Balansard
    • PharmacyHôpital Nord
Article

DOI: 10.1007/BF01875552

Cite this article as:
Langlois-Karaga, A., Bues-Charbit, M., Davignon, A. et al. Pharm World Sci (1995) 17: 12. doi:10.1007/BF01875552

Abstract

A double-blind randomized placebo-controlled study was carried out to evaluate the efficacy and the cost of selective digestive decontamination (SDD) to prevent nosocomial pneumonia in multiple-trauma patients. Nosocomial infections, particularly pneumonia, were more frequent in the placebo group. The most common infectious agent wasStaphylococcus: Staphylococcus aureus in the placebo group andStaphylococcus epidermidis in the SDD group. Methicillin-resistantStaphylococcus epidermidis was detected more often in the SDD group. No methicillin-resistantStaphylococcus aureus was observed in this study. Fewer patients in the SDD group required antibiotherapy. SDD resulted in a saving of about 41% in drug expenditure.

Keywords

AntibioticsBacteriaClinical trialsCosts and cost analysisDrug utilizationInfectionMultiple traumaSelective digestive decontamination

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1995